ABP-450 not checked
Daewoong Pharmaceutical Co. LTD. · AEON Biopharma, Inc. · DWP450
FollowEvery change as it happens, and a Monday email
Trials
1 active
7 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Glabellar Lines
- Main trialPhase 3
- “Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines”In the company’s words, NCT07783763 on ClinicalTrials.gov
- Other names
- prabotulinumtoxinA · DWP450
- Given with
- Botox (Allergan)Other companies’ drugs in its trials
Coming up1
- May 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | May 2028 | Study of DWP450 in Japanese Subjects With Glabellar Lines | |
| Phase 3Completed | 24 Nov 2020 | DWP450 for Treating Moderate to Severe Glabellar Lines | |
| Phase 3Completed | 7 Jan 2021 | Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy | |
| Phase 2Completed | 11 Jul 2022 | A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia | |
| Phase 2Completed | 24 Jul 2023 | Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia | |
| Phase 2Completed | 19 Jun 2024 | Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults | |
| Phase 2Terminated | 31 Jul 2024 | Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026